Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00095732
Status:
COMPLETED
Last Update Posted:
2014-10-17
First Post:
2004-11-09
Brief Title:
Oral TheraCLEC - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency
Sponsor:
Anthera Pharmaceuticals
Organization:
Anthera Pharmaceuticals
Study Overview
Official Title:
A Phase 2 Randomized Double Blind Parallel Dose Ranging Study of Oral TheraCLEC - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency
Status:
COMPLETED
Status Verified Date:
2014-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the most effective dose of a new enzyme therapy on oral nutrient absorption in cystic fibrosis CF subjects with exocrine pancreatic insufficiency
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| TC-2A | OTHER | AltusAlnara | None |
| I5L-MC-TCAA | OTHER | None | None |